Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 28, Issue 5, Pages 197-199Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2007.03.003
Keywords
-
Categories
Ask authors/readers for more resources
Progress in understanding the genetic changes that drive tumorigenesis has enabled the development of molecularly targeted anticancer therapy. The first small molecule targeted to a specific protein was imatinib mesylate (Gleevec, ST1571), which is used to treat chronic myeloid leukemia (CML). A recent article presents a computational model with which to study the treatment response in CML patients and investigates the effect that imatinib exerts on leukemic stem cells. Here, I discuss insights derived from this study and their implications for imatinib therapy against CML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available